PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
58 hedge funds and large institutions have $77.3M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
12% more funds holding
Funds holding: 52 → 58 (+6)
68% less capital invested
Capital invested by funds: $245M → $77.3M (-$168M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.28M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$1.04M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$944K |
| 4 |
Goldman Sachs
New York
|
+$876K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$841K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$11.2M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.85M |
| 3 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$1.41M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.15M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$893K |
PHAS Hedge Fund Activity: Q3 2019 in Review
58 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q3 2019, worth a combined $77.3M — down 68% from $245M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PHAS positions and 7 closed out — a net gain of 6 holders — while 21 added to existing stakes and 12 trimmed.
The largest buyer was DAFNA Capital Management, adding an estimated $1.28M. The largest seller was Deerfield Management, exiting entirely with an estimated $11.2M sold.
- 58 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q3 2019, up from 52 in Q2 2019.
- Funds reported $77.3M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q3 2019, down 68% quarter-over-quarter.
- 13 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 7 closed out, a net change of +6 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was DAFNA Capital Management, an estimated $1.28M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was Deerfield Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q3 2019.